Cargando…

Hypoprothrombinemia During Cefmetazole Treatment: A Case Report

Patient: Female, 76-year-old Final Diagnosis: Drug induced hypoprothrombinemia Symptoms: Abdominal pain • fever • loss of appetite Medication: — Clinical Procedure: Blood tests • CT scan Specialty: Infectious Diseases OBJECTIVE: Unusual clinical course BACKGROUND: Cefmetazole (CMZ), containing an N-...

Descripción completa

Detalles Bibliográficos
Autores principales: Haba, Yuichiro, Akizuki, Hikaru, Hashiguchi, Naoyuki, Naito, Toshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340825/
https://www.ncbi.nlm.nih.gov/pubmed/35891595
http://dx.doi.org/10.12659/AJCR.936712
_version_ 1784760478183981056
author Haba, Yuichiro
Akizuki, Hikaru
Hashiguchi, Naoyuki
Naito, Toshio
author_facet Haba, Yuichiro
Akizuki, Hikaru
Hashiguchi, Naoyuki
Naito, Toshio
author_sort Haba, Yuichiro
collection PubMed
description Patient: Female, 76-year-old Final Diagnosis: Drug induced hypoprothrombinemia Symptoms: Abdominal pain • fever • loss of appetite Medication: — Clinical Procedure: Blood tests • CT scan Specialty: Infectious Diseases OBJECTIVE: Unusual clinical course BACKGROUND: Cefmetazole (CMZ), containing an N-methyl-tetrazole-thiol (NMTT) side chain, is a therapeutic option for diverticulitis in Japan. Cephems containing an NMTT, a methyl-thiadiazol, and a thiadiazolethiol side chain are known to induce coagulation disorders. CASE REPORT: A 76-year-old woman developed hypoprothrombinemia after receiving oral levofloxacin (LVFX) 250 mg q24h for 2 days followed by intravenous CMZ 2 g q8h for sigmoid diverticulitis. On day 5 of CMZ administration (after 12 doses in total), black stool was observed. On the following day (after 14 doses), prothrombin time (PT) prolongation was noted; PT and international normalized ratio (INR) were 37.1 s and 2.47, respectively. We diagnosed the patient with hypoprothrombinemia because of vitamin K deficiency caused by markedly elevated protein levels induced by vitamin K absence or antagonist-II on day 6 of CMZ administration. Intravenous vitamin K administration and CMZ cessation rapidly restored PT and led to the disappearance of black stool. CONCLUSIONS: The causes of vitamin K deficiency were considered to be an impaired vitamin K cycle due to CMZ and decreased vitamin K intake because of malnutrition. These findings are consistent with CMZ’s reported adverse effects. Decreased vitamin K production due to alterations in the gut bacterial flora by LVFX and CMZ was also postulated as a cause. If a bleeding tendency is noted during diverticulitis treatment with NMTT-containing cephems, switching to intravenous quinolones or carbapenems is recommended. It remains unclear how this reaction can be avoided; however, prudent monitoring of bleeding signs and PT-INR is recommended.
format Online
Article
Text
id pubmed-9340825
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-93408252022-08-15 Hypoprothrombinemia During Cefmetazole Treatment: A Case Report Haba, Yuichiro Akizuki, Hikaru Hashiguchi, Naoyuki Naito, Toshio Am J Case Rep Articles Patient: Female, 76-year-old Final Diagnosis: Drug induced hypoprothrombinemia Symptoms: Abdominal pain • fever • loss of appetite Medication: — Clinical Procedure: Blood tests • CT scan Specialty: Infectious Diseases OBJECTIVE: Unusual clinical course BACKGROUND: Cefmetazole (CMZ), containing an N-methyl-tetrazole-thiol (NMTT) side chain, is a therapeutic option for diverticulitis in Japan. Cephems containing an NMTT, a methyl-thiadiazol, and a thiadiazolethiol side chain are known to induce coagulation disorders. CASE REPORT: A 76-year-old woman developed hypoprothrombinemia after receiving oral levofloxacin (LVFX) 250 mg q24h for 2 days followed by intravenous CMZ 2 g q8h for sigmoid diverticulitis. On day 5 of CMZ administration (after 12 doses in total), black stool was observed. On the following day (after 14 doses), prothrombin time (PT) prolongation was noted; PT and international normalized ratio (INR) were 37.1 s and 2.47, respectively. We diagnosed the patient with hypoprothrombinemia because of vitamin K deficiency caused by markedly elevated protein levels induced by vitamin K absence or antagonist-II on day 6 of CMZ administration. Intravenous vitamin K administration and CMZ cessation rapidly restored PT and led to the disappearance of black stool. CONCLUSIONS: The causes of vitamin K deficiency were considered to be an impaired vitamin K cycle due to CMZ and decreased vitamin K intake because of malnutrition. These findings are consistent with CMZ’s reported adverse effects. Decreased vitamin K production due to alterations in the gut bacterial flora by LVFX and CMZ was also postulated as a cause. If a bleeding tendency is noted during diverticulitis treatment with NMTT-containing cephems, switching to intravenous quinolones or carbapenems is recommended. It remains unclear how this reaction can be avoided; however, prudent monitoring of bleeding signs and PT-INR is recommended. International Scientific Literature, Inc. 2022-07-27 /pmc/articles/PMC9340825/ /pubmed/35891595 http://dx.doi.org/10.12659/AJCR.936712 Text en © Am J Case Rep, 2022 https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Articles
Haba, Yuichiro
Akizuki, Hikaru
Hashiguchi, Naoyuki
Naito, Toshio
Hypoprothrombinemia During Cefmetazole Treatment: A Case Report
title Hypoprothrombinemia During Cefmetazole Treatment: A Case Report
title_full Hypoprothrombinemia During Cefmetazole Treatment: A Case Report
title_fullStr Hypoprothrombinemia During Cefmetazole Treatment: A Case Report
title_full_unstemmed Hypoprothrombinemia During Cefmetazole Treatment: A Case Report
title_short Hypoprothrombinemia During Cefmetazole Treatment: A Case Report
title_sort hypoprothrombinemia during cefmetazole treatment: a case report
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340825/
https://www.ncbi.nlm.nih.gov/pubmed/35891595
http://dx.doi.org/10.12659/AJCR.936712
work_keys_str_mv AT habayuichiro hypoprothrombinemiaduringcefmetazoletreatmentacasereport
AT akizukihikaru hypoprothrombinemiaduringcefmetazoletreatmentacasereport
AT hashiguchinaoyuki hypoprothrombinemiaduringcefmetazoletreatmentacasereport
AT naitotoshio hypoprothrombinemiaduringcefmetazoletreatmentacasereport